A CpG island methylator phenotype of colorectal cancer that is contiguous with conventional adenomas, but not serrated polyps

Hokazono,Koji; Ueki,Takashi; Nagayoshi,Kinuko; Nishioka,Yasunobu; Hatae,Tatsunobu; Koga,Yutaka; Hirahashi,Minako; Oda,Yoshinao; Tanaka,Masao

doi:10.3892/ol.2014.2430

A CpG island methylator phenotype of colorectal cancer that is contiguous with conventional adenomas, but not serrated polyps

Authors:
- Koji Hokazono
- Takashi Ueki
- Kinuko Nagayoshi
- Yasunobu Nishioka
- Tatsunobu Hatae
- Yutaka Koga
- Minako Hirahashi
- Yoshinao Oda
- Masao Tanaka
View Affiliations

Affiliations: Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka 812‑8582, Japan, Department of Anatomical Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka 812‑8582, Japan
Published online on: August 8, 2014 https://doi.org/10.3892/ol.2014.2430
Pages: 1937-1944

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A subset of colorectal cancers (CRCs) harbor the CpG island methylator phenotype (CIMP), with concurrent multiple promoter hypermethylation of tumor‑related genes. A serrated pathway in which CIMP is developed from serrated polyps is proposed. The present study characterized CIMP and morphologically examined precursor lesions of CIMP. In total, 104 CRCs treated between January 1996 and December 2004 were examined. Aberrant promoter methylation of 15 cancer‑related genes was analyzed. CIMP status was classified according to the number of methylated genes and was correlated with the clinicopathological features, including the concomitant polyps in and around the tumors. The frequency of aberrant methylation in each CRC showed a bimodal pattern, and the CRCs were classified as CIMP‑high (CIMP‑H), CIMP‑low (CIMP‑L) and CIMP‑negative (CIMP‑N). CIMP‑H was associated with aberrant methylation of MLH1 (P=0.005) and with an improved recurrence‑free survival (RFS) rate following curative resection compared with CIMP‑L/N (five‑year RFS rate, 93.8 vs. 67.1%; P=0.044), while CIMP‑N tumors were associated with frequent distant metastases at diagnosis (P=0.023). No concomitant serrated lesions were present in the tumors, whereas conventional adenoma was contiguous with 11 (10.6%) of 104 CRCs, including four CIMP‑H CRCs. CIMP‑H was classified in CRCs by a novel CIMP marker panel and the presence of concomitant tumors revealed that certain CIMP‑H CRCs may have arisen from conventional adenomas.

View Figures

View References

1	Shen L and Issa JP: Epigenetics in colorectal cancer. Curr Opin Gastroenterol. 18:68–73. 2002.
2	Toyota M, Ahuja N, Ohe-Toyota M, et al: CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA. 96:8681–8686. 1999.
3	Hawkins N, Norrie M, Cheong K, et al: CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology. 122:1376–1387. 2002.
4	Ogino S, Nosho K, Kirkner GJ, et al: CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 58:90–96. 2009.
5	Weisenberger DJ, Siegmund KD, Campan M, et al: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 38:787–793. 2006.
6	Shen L, Toyota M, Kondo Y, et al: Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA. 104:18654–18659. 2007.
7	Ahn JB, Chung WB, Maeda O, et al: DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer. 117:1847–1854. 2011.
8	Van Rijnsoever M, Grieu F, Elsaleh H, et al: Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut. 51:797–802. 2002.
9	Iacopetta B, Kawakami K and Watanabe T: Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup? Int J Clin Oncol. 13:498–503. 2008.
10	Shen L, Catalano PJ, Benson AB III, et al: Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res. 13:6093–6098. 2007.
11	Van Rijnsoever M, Elsaleh H, Joseph D, et al: CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res. 9:2898–2903. 2003.
12	Arnold CN, Goel A, Compton C, et al: Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer. Cancer Biol Ther. 3:73–78. 2004.
13	Samowitz WS, Albertsen H, Herrick J, et al: Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology. 129:837–845. 2005.
14	Ogino S, Kawasaki T, Kirkner GJ, et al: Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn. 9:305–314. 2007.
15	Hawkins NJ and Ward RL: Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. J Natl Cancer Inst. 93:1307–1313. 2001.
16	Gaiser T, Meinhardt S, Hirsch D, et al: Molecular patterns in the evolution of serrated lesion of the colorectum. Int J Cancer. 132:1800–1810. 2013.
17	George SM, Mäkinen MJ, Jernvall P, et al: Classification of advanced colorectal carcinomas by tumor edge morphology: evidence for different pathogenesis and significance of polypoid and nonpolypoid tumors. Cancer. 89:1901–1909. 2000.
18	Ueki T, Toyota M, Skinner H, et al: Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res. 61:8540–8546. 2001.
19	Herman JG, Graff JR, Myöhänen S, et al: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 93:9821–9826. 1996.
20	Yamashita K, Dai T, Dai Y, et al: Genetics supersedes epigenetics in colon cancer phenotype. Cancer Cell. 4:121–131. 2003.
21	Iacopetta B, Grieu F, Li W, et al: APC gene methylation is inversely correlated with features of the CpG island methylator phenotype in colorectal cancer. Int J Cancer. 119:2272–2278. 2006.
22	Chan AO, Issa JP, Morris JS, et al: Concordant CpG island methylation in hyperplastic polyposis. Am J Pathol. 160:529–536. 2002.
23	Park SJ, Rashid A, Lee JH, et al: Frequent CpG island methylation in serrated adenomas of the colorectum. Am J Pathol. 162:815–822. 2003.
24	Young J and Jass JR: The case for a genetic predisposition to serrated neoplasia in the colorectum: hypothesis and review of the literature. Cancer Epidemiol Biomarkers Prev. 15:1778–1784. 2006.
25	Jass JR: Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 50:113–130. 2007.
26	Barault L, Charon-Barra C, Jooste V, et al: Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res. 68:8541–8546. 2008.
27	Hutchins G, Southward K, Handley K, et al: Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 29:1261–1270. 2011.
28	Popat S, Hubner R and Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 23:609–618. 2005.
29	Sinicrope FA, Foster NR, Thibodeau SN, et al: DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 103:863–875. 2011.
30	Samowitz WS, Sweeney C, Herrick J, et al: Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 65:6063–6069. 2005.
31	Ang PW, Loh M, Liem N, et al: Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features. BMC Cancer. 10:2272010.
32	Carethers JM, Smith EJ, Behling CA, et al: Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology. 126:394–401. 2004.
33	Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 349:247–57. 2003.
34	Jover R, Nguyen TP, Perez-Carbonell L, et al: 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology. 140:1174–1181. 2011.
35	Matsuzaki K, Deng G, Tanaka H, et al: The relationship between global methylation level, loss of heterozygosity, and microsatellite instability in sporadic colorectal cancer. Clin Cancer Res. 11:8564–8569. 2005.
36	Rodriguez J, Frigola J, Vendrell E, et al: Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res. 66:8462–8468. 2006.
37	Derks S, Postma C, Carvalho B, et al: Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations. Carcinogenesis. 29:434–439. 2008.
38	Goel A, Nagasaka T, Arnold CN, et al: The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology. 132:127–138. 2007.
39	Ogino S, Nosho K, Kirkner GJ, et al: A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst. 100:1734–1738. 2008.
40	Roth AD, Tejpar S, Delorenzi M, et al: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60–00 trial. J Clin Oncol. 28:466–474. 2010.
41	He L, Vasiliou K and Nebert DW: Analysis and update of the human solute carrier (SLC) gene superfamily. Hum Genomics. 3:195–206. 2009.
42	Arai E, Chiku S, Mori T, et al: Single-CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas. Carcinogenesis. 33:1487–1493. 2012.
43	Etcheverry A, Aubry M, de Tayrac M, et al: DNA methylation in glioblastoma: impact on gene expression and clinical outcome. BMC genomics. 11:7012010.
44	Huang Y and Sadée W: Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett. 239:168–182. 2006.
45	Li H, Myeroff L, Smiraglia D, et al: SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci USA. 100:8412–8417. 2003.